Cellcept: Clinical Trials

68 trials of Cellcept, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

40 completed, 9 terminated, 7 recruiting, 6 active not recruiting. 68 Phase 1, 25 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 168Completed 40, Terminated 9, Recruiting 7, Active not recruiting 6, Withdrawn 3, Unknown 2, Suspended 1
Phase 225Completed 15, Recruiting 4, Active not recruiting 3, Terminated 1, Unknown 1, Withdrawn 1

Follow Cellcept: new trials by email Literature Review of Cellcept trials Research Report on Cellcept

Trials (filtered) newest first · largest first

All 68 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
Biospecimen Collection, Busulfan, Computed Tomography - Acute Myeloid Leukemia, Graft Versus Host Disease
Phase 1RecruitingCity of Hope Medical Center152026-06-122026-11-09
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia
Phase 1RecruitingOHSU Knight Cancer Institute402026-04-212026-10-05
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Active not recruitingOssium Health, Inc.122024-08-162026-09-10
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Mycophenolate Mofetil, Allopurinol, Irinotecan - Small-cell Lung Cancer, Small Cell Lung Carcinoma
Phase 1TerminatedWashington University School of Medicine172023-02-272024-12-05
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy - Astrocytoma, Glioblastoma
Phase 1Active not recruitingNorthwestern University862022-08-082026-08-26
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan - Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies
Phase 1Active not recruitingStanford University662021-09-072026-05-12
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
Etoposide, Fludarabine Phosphate, Hematopoietic Cell Transplantation - Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor
Phase 1WithdrawnM.D. Anderson Cancer Center2021-01-142024-10-26
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
Phase 1RecruitingFred Hutchinson Cancer Center1202020-12-032026-09-17
Haplo Peripheral Blood Sct In GVHD Prevention
FLUDARABINE, CYCLOPHOSPHAMIDE, TBI - GVHD, AML
Phase 1CompletedZachariah Michael DeFilipp252020-08-142025-07-20
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide - Non-Malignant Neoplasm
Phase 1 / Phase 2RecruitingFred Hutchinson Cancer Center402020-06-162026-06-17
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
Allogeneic Hematopoietic Stem Cell Transplantation, Bendamustine, Cyclophosphamide - Hematopoietic and Lymphoid System Neoplasm
Phase 1 / Phase 2RecruitingM.D. Anderson Cancer Center252020-03-132026-07-16
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Phase 1 / Phase 2RecruitingFred Hutchinson Cancer Center302019-07-102026-06-22
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Phase 1 / Phase 2RecruitingFred Hutchinson Cancer Center752017-10-242026-06-22
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission
Phase 1 / Phase 2Active not recruitingRoswell Park Cancer Institute352017-08-092026-04-14
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center742017-07-302026-06-10
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine - Secondary Myelofibrosis
Phase 1Active not recruitingCity of Hope Medical Center222017-06-212026-08-21
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
Fludarabine, Busulfan, Cyclophosphamide - Non-Hodgkin's Lymphoma, Acute Leukemia in Remission
Phase 1CompletedH. Lee Moffitt Cancer Center and Research Institute322017-01-312021-09-16
Treg Therapy in Subclinical Inflammation in Kidney Transplantation
Polyclonal Regulatory T Cells, Everolimus, Tacrolimus - Kidney Transplant, Adult Living Donor Kidney Transplant Recipients
Phase 1 / Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)322016-09-202026-09-24
Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
Cyclophosphamide, Fludarabine, Tacrolimus - Lupus Erythematosus, Graft-versus-host Disease
Phase 1 / Phase 2TerminatedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins12016-09-132019-10-02
Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease
Alemtuzumab, Cyclophosphamide, Mycophenolate mofetil - Sickle Cell Disease
Phase 1TerminatedWashington University School of Medicine12016-04-262022-02-14

Showing 20 of 68. Sign in to see all of them.

Conditions studied

Leukemia, Myeloid, Acute (23)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (18)  ·  Hodgkin Disease (14)  ·  Leukemia, Myelomonocytic, Chronic (13)  ·  Lymphoma, Non-Hodgkin (13)  ·  Myelodysplastic Syndromes (12)  ·  Multiple Myeloma (11)  ·  Anemia, Refractory, with Excess of Blasts (9)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (9)  ·  Leukemia (8)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (8)  ·  Myeloproliferative Disorders (7)  ·  Graft vs Host Disease (6)  ·  Leukemia, Biphenotypic, Acute (6)  ·  Lymphoma (6)

Sponsors

Fred Hutchinson Cancer Center (21)  ·  M.D. Anderson Cancer Center (10)  ·  Dr. Reddy's Laboratories Limited (4)  ·  City of Hope Medical Center (3)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  Northwestern University (2)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2)  ·  Stanford University (2)  ·  Washington University School of Medicine (2)  ·  Astellas Pharma Inc (1)  ·  Boston University (1)  ·  Case Comprehensive Cancer Center (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Hoffmann-La Roche (1)  ·  Northwell Health (1)

Countries

United States (58)  ·  Italy (5)  ·  India (4)  ·  Germany (3)  ·  New Zealand (1)  ·  Russia (1)  ·  South Korea (1)

Top investigators

Brenda Sandmaier (6)  ·  David Maloney (3)  ·  Elizabeth Shpall, MD (2)  ·  Johnnie Orozco (2)  ·  Phuong Vo (2)  ·  T Gitanjali, MD (2)  ·  Amandeep Salhotra (1)  ·  Ann Woolfrey (1)  ·  Brandon Triplett, MD (1)  ·  Brenda M. Sandmaier (1)  ·  Chitra Hosing (1)  ·  Colleen Delaney (1)  ·  Damian Green (1)  ·  Daniel Morgensztern, M.D. (1)

Results publications

PMID 32499241, PMID 18035553, PMID 18424759, PMID 18554762, PMID 18557726, PMID 19066739, PMID 19786617, PMID 20236866, PMID 21868572, PMID 23234514, PMID 23607606, PMID 23903014, PMID 25778529, PMID 29353109, PMID 30335787, PMID 31397274, PMID 31582553, PMID 32710011, PMID 33635333, PMID 34312462, PMID 37939122

NIH funding

P30CA015704 (15), P01CA078902 (5), P01CA044991 (4), P01CA018029 (2), P01CA148600 (2), P30CA033572 (2), K12HD043494 (1), P01CA049639 (1), P01HL036444 (1), P01HL122173 (1), P30CA014599 (1), P30CA016672 (1), P30CA036727 (1), P30CA043703 (1), P30CA060553 (1)